FDA Approves Regeneron Sanofi Treatment For Rare Autoimmune Skin Disorder

benzinga.com/news/fda/25/06/46028780/fda-approves-regeneronm-sanofi-treatment-for-rare-autoimmune-skin-disorder

The U.S. Food and Drug Administration (FDA) on Friday approved Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) and Sanofi SA’s (NASDAQ:SNY) Dupixent (dupilumab) for adult patients with bullous pemphigoid (BP), a rare, chronic autoimmune skin disorder.
BP primarily affects elderly patients…

This story appeared on benzinga.com, 2025-06-20 14:47:56.
The Entire Business World on a Single Page. Free to Use →